Global Prostacyclin
Global Prostacyclin

Prostacyclin Comprehensive Study by Type (Epoprostenol Sodium, Treprostinil, Iloprost, Beraprost Sodium), Application (Hospitals, Medical Research Center, Pharmaceutical Factory, Others), End Use (Injection, Oral, Inhalation) Players and Region - Global Market Outlook to 2025

Prostacyclin Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 230 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Vendors landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Key Vendors of Prostacyclin Market Study:
United Therapeutics (United States), Actelion (J & J) (Switzerland), GlaxoSmithKline (United Kingdom), Teva (Israel), Toray (Japan), Tide Pharma (China) and Bayer AG (Germany)

In the last few years, Global market of Prostacyclin developed rapidly. Major factors driving the market are Increase in the Treatment of Many Different Cardiovascular Diseases.

On the basis of product type, the Prostacyclin market is segmented by Epoprostenol Sodium, Treprostinil, Iloprost and Beraprost Sodium.

On the basis of applications, the Prostacyclin market is segmented by Hospitals, Medical Research Center, Pharmaceutical Factory and Others.

.

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Prostacyclin market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Prostacyclin market.
Identification of total players or companies operating in the global market which is further concentrated to a fewer or most impacting players which is considered under the reportís scope. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Providers of Prostacyclin, End-Users, Potential Investors, Regulatory Bodies, Market Research Firms and Others.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Epoprostenol Sodium
  • Treprostinil
  • Iloprost
  • Beraprost Sodium
By Application
  • Hospitals
  • Medical Research Center
  • Pharmaceutical Factory
  • Others
By End Use
  • Injection
  • Oral
  • Inhalation

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Treatment of Many Different Cardiovascular Diseases
    • 3.3. Market Challenges
      • 3.3.1. High Competition among Established Players
    • 3.4. Market Trends
      • 3.4.1. Advancement in Technology for Treatment of Heart Problem
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prostacyclin, by Type, Application, End Use and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Prostacyclin (Value)
      • 5.2.1. Global Prostacyclin by: Type (Value)
        • 5.2.1.1. Epoprostenol Sodium
        • 5.2.1.2. Treprostinil
        • 5.2.1.3. Iloprost
        • 5.2.1.4. Beraprost Sodium
      • 5.2.2. Global Prostacyclin by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Medical Research Center
        • 5.2.2.3. Pharmaceutical Factory
        • 5.2.2.4. Others
      • 5.2.3. Global Prostacyclin by: End Use (Value)
        • 5.2.3.1. Injection
        • 5.2.3.2. Oral
        • 5.2.3.3. Inhalation
      • 5.2.4. Global Prostacyclin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Prostacyclin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. United Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Actelion (J & J) (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Toray (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Tide Pharma (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Prostacyclin Sale, by Type, Application, End Use and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Prostacyclin (Value)
      • 7.2.1. Global Prostacyclin by: Type (Value)
        • 7.2.1.1. Epoprostenol Sodium
        • 7.2.1.2. Treprostinil
        • 7.2.1.3. Iloprost
        • 7.2.1.4. Beraprost Sodium
      • 7.2.2. Global Prostacyclin by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Medical Research Center
        • 7.2.2.3. Pharmaceutical Factory
        • 7.2.2.4. Others
      • 7.2.3. Global Prostacyclin by: End Use (Value)
        • 7.2.3.1. Injection
        • 7.2.3.2. Oral
        • 7.2.3.3. Inhalation
      • 7.2.4. Global Prostacyclin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prostacyclin: by Type(USD Million)
  • Table 2. Prostacyclin Epoprostenol Sodium , by Region USD Million (2014-2019)
  • Table 3. Prostacyclin Treprostinil , by Region USD Million (2014-2019)
  • Table 4. Prostacyclin Iloprost , by Region USD Million (2014-2019)
  • Table 5. Prostacyclin Beraprost Sodium , by Region USD Million (2014-2019)
  • Table 6. Prostacyclin: by Application(USD Million)
  • Table 7. Prostacyclin Hospitals , by Region USD Million (2014-2019)
  • Table 8. Prostacyclin Medical Research Center , by Region USD Million (2014-2019)
  • Table 9. Prostacyclin Pharmaceutical Factory , by Region USD Million (2014-2019)
  • Table 10. Prostacyclin Others , by Region USD Million (2014-2019)
  • Table 11. Prostacyclin: by End Use(USD Million)
  • Table 12. Prostacyclin Injection , by Region USD Million (2014-2019)
  • Table 13. Prostacyclin Oral , by Region USD Million (2014-2019)
  • Table 14. Prostacyclin Inhalation , by Region USD Million (2014-2019)
  • Table 15. South America Prostacyclin, by Country USD Million (2014-2019)
  • Table 16. South America Prostacyclin, by Type USD Million (2014-2019)
  • Table 17. South America Prostacyclin, by Application USD Million (2014-2019)
  • Table 18. South America Prostacyclin, by End Use USD Million (2014-2019)
  • Table 19. Brazil Prostacyclin, by Type USD Million (2014-2019)
  • Table 20. Brazil Prostacyclin, by Application USD Million (2014-2019)
  • Table 21. Brazil Prostacyclin, by End Use USD Million (2014-2019)
  • Table 22. Argentina Prostacyclin, by Type USD Million (2014-2019)
  • Table 23. Argentina Prostacyclin, by Application USD Million (2014-2019)
  • Table 24. Argentina Prostacyclin, by End Use USD Million (2014-2019)
  • Table 25. Rest of South America Prostacyclin, by Type USD Million (2014-2019)
  • Table 26. Rest of South America Prostacyclin, by Application USD Million (2014-2019)
  • Table 27. Rest of South America Prostacyclin, by End Use USD Million (2014-2019)
  • Table 28. Asia Pacific Prostacyclin, by Country USD Million (2014-2019)
  • Table 29. Asia Pacific Prostacyclin, by Type USD Million (2014-2019)
  • Table 30. Asia Pacific Prostacyclin, by Application USD Million (2014-2019)
  • Table 31. Asia Pacific Prostacyclin, by End Use USD Million (2014-2019)
  • Table 32. China Prostacyclin, by Type USD Million (2014-2019)
  • Table 33. China Prostacyclin, by Application USD Million (2014-2019)
  • Table 34. China Prostacyclin, by End Use USD Million (2014-2019)
  • Table 35. Japan Prostacyclin, by Type USD Million (2014-2019)
  • Table 36. Japan Prostacyclin, by Application USD Million (2014-2019)
  • Table 37. Japan Prostacyclin, by End Use USD Million (2014-2019)
  • Table 38. India Prostacyclin, by Type USD Million (2014-2019)
  • Table 39. India Prostacyclin, by Application USD Million (2014-2019)
  • Table 40. India Prostacyclin, by End Use USD Million (2014-2019)
  • Table 41. South Korea Prostacyclin, by Type USD Million (2014-2019)
  • Table 42. South Korea Prostacyclin, by Application USD Million (2014-2019)
  • Table 43. South Korea Prostacyclin, by End Use USD Million (2014-2019)
  • Table 44. Taiwan Prostacyclin, by Type USD Million (2014-2019)
  • Table 45. Taiwan Prostacyclin, by Application USD Million (2014-2019)
  • Table 46. Taiwan Prostacyclin, by End Use USD Million (2014-2019)
  • Table 47. Australia Prostacyclin, by Type USD Million (2014-2019)
  • Table 48. Australia Prostacyclin, by Application USD Million (2014-2019)
  • Table 49. Australia Prostacyclin, by End Use USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Prostacyclin, by Type USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Prostacyclin, by Application USD Million (2014-2019)
  • Table 52. Rest of Asia-Pacific Prostacyclin, by End Use USD Million (2014-2019)
  • Table 53. Europe Prostacyclin, by Country USD Million (2014-2019)
  • Table 54. Europe Prostacyclin, by Type USD Million (2014-2019)
  • Table 55. Europe Prostacyclin, by Application USD Million (2014-2019)
  • Table 56. Europe Prostacyclin, by End Use USD Million (2014-2019)
  • Table 57. Germany Prostacyclin, by Type USD Million (2014-2019)
  • Table 58. Germany Prostacyclin, by Application USD Million (2014-2019)
  • Table 59. Germany Prostacyclin, by End Use USD Million (2014-2019)
  • Table 60. France Prostacyclin, by Type USD Million (2014-2019)
  • Table 61. France Prostacyclin, by Application USD Million (2014-2019)
  • Table 62. France Prostacyclin, by End Use USD Million (2014-2019)
  • Table 63. Italy Prostacyclin, by Type USD Million (2014-2019)
  • Table 64. Italy Prostacyclin, by Application USD Million (2014-2019)
  • Table 65. Italy Prostacyclin, by End Use USD Million (2014-2019)
  • Table 66. United Kingdom Prostacyclin, by Type USD Million (2014-2019)
  • Table 67. United Kingdom Prostacyclin, by Application USD Million (2014-2019)
  • Table 68. United Kingdom Prostacyclin, by End Use USD Million (2014-2019)
  • Table 69. Netherlands Prostacyclin, by Type USD Million (2014-2019)
  • Table 70. Netherlands Prostacyclin, by Application USD Million (2014-2019)
  • Table 71. Netherlands Prostacyclin, by End Use USD Million (2014-2019)
  • Table 72. Rest of Europe Prostacyclin, by Type USD Million (2014-2019)
  • Table 73. Rest of Europe Prostacyclin, by Application USD Million (2014-2019)
  • Table 74. Rest of Europe Prostacyclin, by End Use USD Million (2014-2019)
  • Table 75. MEA Prostacyclin, by Country USD Million (2014-2019)
  • Table 76. MEA Prostacyclin, by Type USD Million (2014-2019)
  • Table 77. MEA Prostacyclin, by Application USD Million (2014-2019)
  • Table 78. MEA Prostacyclin, by End Use USD Million (2014-2019)
  • Table 79. Middle East Prostacyclin, by Type USD Million (2014-2019)
  • Table 80. Middle East Prostacyclin, by Application USD Million (2014-2019)
  • Table 81. Middle East Prostacyclin, by End Use USD Million (2014-2019)
  • Table 82. Africa Prostacyclin, by Type USD Million (2014-2019)
  • Table 83. Africa Prostacyclin, by Application USD Million (2014-2019)
  • Table 84. Africa Prostacyclin, by End Use USD Million (2014-2019)
  • Table 85. North America Prostacyclin, by Country USD Million (2014-2019)
  • Table 86. North America Prostacyclin, by Type USD Million (2014-2019)
  • Table 87. North America Prostacyclin, by Application USD Million (2014-2019)
  • Table 88. North America Prostacyclin, by End Use USD Million (2014-2019)
  • Table 89. United States Prostacyclin, by Type USD Million (2014-2019)
  • Table 90. United States Prostacyclin, by Application USD Million (2014-2019)
  • Table 91. United States Prostacyclin, by End Use USD Million (2014-2019)
  • Table 92. Canada Prostacyclin, by Type USD Million (2014-2019)
  • Table 93. Canada Prostacyclin, by Application USD Million (2014-2019)
  • Table 94. Canada Prostacyclin, by End Use USD Million (2014-2019)
  • Table 95. Mexico Prostacyclin, by Type USD Million (2014-2019)
  • Table 96. Mexico Prostacyclin, by Application USD Million (2014-2019)
  • Table 97. Mexico Prostacyclin, by End Use USD Million (2014-2019)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Prostacyclin: by Type(USD Million)
  • Table 106. Prostacyclin Epoprostenol Sodium , by Region USD Million (2020-2025)
  • Table 107. Prostacyclin Treprostinil , by Region USD Million (2020-2025)
  • Table 108. Prostacyclin Iloprost , by Region USD Million (2020-2025)
  • Table 109. Prostacyclin Beraprost Sodium , by Region USD Million (2020-2025)
  • Table 110. Prostacyclin: by Application(USD Million)
  • Table 111. Prostacyclin Hospitals , by Region USD Million (2020-2025)
  • Table 112. Prostacyclin Medical Research Center , by Region USD Million (2020-2025)
  • Table 113. Prostacyclin Pharmaceutical Factory , by Region USD Million (2020-2025)
  • Table 114. Prostacyclin Others , by Region USD Million (2020-2025)
  • Table 115. Prostacyclin: by End Use(USD Million)
  • Table 116. Prostacyclin Injection , by Region USD Million (2020-2025)
  • Table 117. Prostacyclin Oral , by Region USD Million (2020-2025)
  • Table 118. Prostacyclin Inhalation , by Region USD Million (2020-2025)
  • Table 119. South America Prostacyclin, by Country USD Million (2020-2025)
  • Table 120. South America Prostacyclin, by Type USD Million (2020-2025)
  • Table 121. South America Prostacyclin, by Application USD Million (2020-2025)
  • Table 122. South America Prostacyclin, by End Use USD Million (2020-2025)
  • Table 123. Brazil Prostacyclin, by Type USD Million (2020-2025)
  • Table 124. Brazil Prostacyclin, by Application USD Million (2020-2025)
  • Table 125. Brazil Prostacyclin, by End Use USD Million (2020-2025)
  • Table 126. Argentina Prostacyclin, by Type USD Million (2020-2025)
  • Table 127. Argentina Prostacyclin, by Application USD Million (2020-2025)
  • Table 128. Argentina Prostacyclin, by End Use USD Million (2020-2025)
  • Table 129. Rest of South America Prostacyclin, by Type USD Million (2020-2025)
  • Table 130. Rest of South America Prostacyclin, by Application USD Million (2020-2025)
  • Table 131. Rest of South America Prostacyclin, by End Use USD Million (2020-2025)
  • Table 132. Asia Pacific Prostacyclin, by Country USD Million (2020-2025)
  • Table 133. Asia Pacific Prostacyclin, by Type USD Million (2020-2025)
  • Table 134. Asia Pacific Prostacyclin, by Application USD Million (2020-2025)
  • Table 135. Asia Pacific Prostacyclin, by End Use USD Million (2020-2025)
  • Table 136. China Prostacyclin, by Type USD Million (2020-2025)
  • Table 137. China Prostacyclin, by Application USD Million (2020-2025)
  • Table 138. China Prostacyclin, by End Use USD Million (2020-2025)
  • Table 139. Japan Prostacyclin, by Type USD Million (2020-2025)
  • Table 140. Japan Prostacyclin, by Application USD Million (2020-2025)
  • Table 141. Japan Prostacyclin, by End Use USD Million (2020-2025)
  • Table 142. India Prostacyclin, by Type USD Million (2020-2025)
  • Table 143. India Prostacyclin, by Application USD Million (2020-2025)
  • Table 144. India Prostacyclin, by End Use USD Million (2020-2025)
  • Table 145. South Korea Prostacyclin, by Type USD Million (2020-2025)
  • Table 146. South Korea Prostacyclin, by Application USD Million (2020-2025)
  • Table 147. South Korea Prostacyclin, by End Use USD Million (2020-2025)
  • Table 148. Taiwan Prostacyclin, by Type USD Million (2020-2025)
  • Table 149. Taiwan Prostacyclin, by Application USD Million (2020-2025)
  • Table 150. Taiwan Prostacyclin, by End Use USD Million (2020-2025)
  • Table 151. Australia Prostacyclin, by Type USD Million (2020-2025)
  • Table 152. Australia Prostacyclin, by Application USD Million (2020-2025)
  • Table 153. Australia Prostacyclin, by End Use USD Million (2020-2025)
  • Table 154. Rest of Asia-Pacific Prostacyclin, by Type USD Million (2020-2025)
  • Table 155. Rest of Asia-Pacific Prostacyclin, by Application USD Million (2020-2025)
  • Table 156. Rest of Asia-Pacific Prostacyclin, by End Use USD Million (2020-2025)
  • Table 157. Europe Prostacyclin, by Country USD Million (2020-2025)
  • Table 158. Europe Prostacyclin, by Type USD Million (2020-2025)
  • Table 159. Europe Prostacyclin, by Application USD Million (2020-2025)
  • Table 160. Europe Prostacyclin, by End Use USD Million (2020-2025)
  • Table 161. Germany Prostacyclin, by Type USD Million (2020-2025)
  • Table 162. Germany Prostacyclin, by Application USD Million (2020-2025)
  • Table 163. Germany Prostacyclin, by End Use USD Million (2020-2025)
  • Table 164. France Prostacyclin, by Type USD Million (2020-2025)
  • Table 165. France Prostacyclin, by Application USD Million (2020-2025)
  • Table 166. France Prostacyclin, by End Use USD Million (2020-2025)
  • Table 167. Italy Prostacyclin, by Type USD Million (2020-2025)
  • Table 168. Italy Prostacyclin, by Application USD Million (2020-2025)
  • Table 169. Italy Prostacyclin, by End Use USD Million (2020-2025)
  • Table 170. United Kingdom Prostacyclin, by Type USD Million (2020-2025)
  • Table 171. United Kingdom Prostacyclin, by Application USD Million (2020-2025)
  • Table 172. United Kingdom Prostacyclin, by End Use USD Million (2020-2025)
  • Table 173. Netherlands Prostacyclin, by Type USD Million (2020-2025)
  • Table 174. Netherlands Prostacyclin, by Application USD Million (2020-2025)
  • Table 175. Netherlands Prostacyclin, by End Use USD Million (2020-2025)
  • Table 176. Rest of Europe Prostacyclin, by Type USD Million (2020-2025)
  • Table 177. Rest of Europe Prostacyclin, by Application USD Million (2020-2025)
  • Table 178. Rest of Europe Prostacyclin, by End Use USD Million (2020-2025)
  • Table 179. MEA Prostacyclin, by Country USD Million (2020-2025)
  • Table 180. MEA Prostacyclin, by Type USD Million (2020-2025)
  • Table 181. MEA Prostacyclin, by Application USD Million (2020-2025)
  • Table 182. MEA Prostacyclin, by End Use USD Million (2020-2025)
  • Table 183. Middle East Prostacyclin, by Type USD Million (2020-2025)
  • Table 184. Middle East Prostacyclin, by Application USD Million (2020-2025)
  • Table 185. Middle East Prostacyclin, by End Use USD Million (2020-2025)
  • Table 186. Africa Prostacyclin, by Type USD Million (2020-2025)
  • Table 187. Africa Prostacyclin, by Application USD Million (2020-2025)
  • Table 188. Africa Prostacyclin, by End Use USD Million (2020-2025)
  • Table 189. North America Prostacyclin, by Country USD Million (2020-2025)
  • Table 190. North America Prostacyclin, by Type USD Million (2020-2025)
  • Table 191. North America Prostacyclin, by Application USD Million (2020-2025)
  • Table 192. North America Prostacyclin, by End Use USD Million (2020-2025)
  • Table 193. United States Prostacyclin, by Type USD Million (2020-2025)
  • Table 194. United States Prostacyclin, by Application USD Million (2020-2025)
  • Table 195. United States Prostacyclin, by End Use USD Million (2020-2025)
  • Table 196. Canada Prostacyclin, by Type USD Million (2020-2025)
  • Table 197. Canada Prostacyclin, by Application USD Million (2020-2025)
  • Table 198. Canada Prostacyclin, by End Use USD Million (2020-2025)
  • Table 199. Mexico Prostacyclin, by Type USD Million (2020-2025)
  • Table 200. Mexico Prostacyclin, by Application USD Million (2020-2025)
  • Table 201. Mexico Prostacyclin, by End Use USD Million (2020-2025)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prostacyclin: by Type USD Million (2014-2019)
  • Figure 5. Global Prostacyclin: by Application USD Million (2014-2019)
  • Figure 6. Global Prostacyclin: by End Use USD Million (2014-2019)
  • Figure 7. South America Prostacyclin Share (%), by Country
  • Figure 8. Asia Pacific Prostacyclin Share (%), by Country
  • Figure 9. Europe Prostacyclin Share (%), by Country
  • Figure 10. MEA Prostacyclin Share (%), by Country
  • Figure 11. North America Prostacyclin Share (%), by Country
  • Figure 12. Global Prostacyclin share by Players 2019 (%)
  • Figure 13. Global Prostacyclin share by Players (Top 3) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. United Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 16. United Therapeutics (United States) Revenue: by Geography 2019
  • Figure 17. Actelion (J & J) (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Actelion (J & J) (Switzerland) Revenue: by Geography 2019
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2019
  • Figure 21. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva (Israel) Revenue: by Geography 2019
  • Figure 23. Toray (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Toray (Japan) Revenue: by Geography 2019
  • Figure 25. Tide Pharma (China) Revenue, Net Income and Gross profit
  • Figure 26. Tide Pharma (China) Revenue: by Geography 2019
  • Figure 27. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 29. Global Prostacyclin: by Type USD Million (2020-2025)
  • Figure 30. Global Prostacyclin: by Application USD Million (2020-2025)
  • Figure 31. Global Prostacyclin: by End Use USD Million (2020-2025)
  • Figure 32. South America Prostacyclin Share (%), by Country
  • Figure 33. Asia Pacific Prostacyclin Share (%), by Country
  • Figure 34. Europe Prostacyclin Share (%), by Country
  • Figure 35. MEA Prostacyclin Share (%), by Country
  • Figure 36. North America Prostacyclin Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • United Therapeutics (United States)
  • Actelion (J & J) (Switzerland)
  • GlaxoSmithKline (United Kingdom)
  • Teva (Israel)
  • Toray (Japan)
  • Tide Pharma (China)
  • Bayer AG (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation